Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. has reported developments tied to molecular genetics diagnostics for early cancer detection and a later corporate transition to the Quantum Cyber name and QUCY ticker. Its company updates have centered on ColoAlert, a non-invasive colorectal cancer screening test marketed in Europe, and PancAlert, an early-stage pancreatic cancer screening candidate using PCR-based multiplex detection of molecular-genetic biomarkers in blood and stool samples.
Recurring news themes include clinical-study and conference disclosures for colorectal and pancreatic cancer detection, commercial distribution and digital-health partnerships, financing activity, strategic updates, board governance changes, and Nasdaq ticker matters.
Mainz Biomed N.V. (NASDAQ:MYNZ) announced the commencement of its stock trading on the Nasdaq Capital Market on Nov. 5, 2021, closing at $9.99 per share, above its public offering price of $5.00. The company successfully completed a public offering of 2,000,000 shares, resulting in gross proceeds of $10 million. Mainz Biomed specializes in molecular genetic diagnostics for early cancer detection, notably the ColoAlert test for colorectal cancer, with plans for FDA approval in 2022. The offering was underwritten by Boustead Securities, LLC.
Mainz Biomed N.V. (Nasdaq:MYNZ) announced the commencement of trading of its shares on the Nasdaq Capital Market as of November 5, 2021, following a public offering. The company priced 2,000,000 common shares at $5.00 each, aiming to raise gross proceeds of $10,000,000. This offering is set to close around November 9, 2021, pending customary conditions. Mainz Biomed specializes in molecular genetic diagnostics, with products like ColoAlert for colorectal cancer detection and PancAlert, a pancreatic cancer screening test.